- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04264143
CED of MTX110 Newly Diagnosed Diffuse Midline Gliomas
A Phase I Study Examining the Feasibility of Intermittent Convection-Enhanced Delivery (CED) of MTX110 for the Treatment of Children With Newly Diagnosed Diffuse Midline Gliomas
The blood brain barrier (BBB) prevents some drugs from successfully reaching the target source. Convection-Enhanced Delivery (CED) is a method of direct infusion of drugs under controlled pressure to the tumor that may reduce systemic side effects of drugs in the patient.
The purpose of this Phase I study is to find the maximum tolerated dose of MTX110 (a water-soluble Panobinostat nanoparticle formulation) and Gadolinium that can be given safely in children with newly diagnosed diffuse midline gliomas. All patients enrolled in the study will receive infusion of MTX110 and Gadolinium delivered with a pump directly into the tumor over 9-11 days.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Diffuse midline gliomas (DMGs), constitute 10% of all pediatric central nervous system (CNS) tumors. Subjects with Diffuse Intrinsic Pontine Gliomas (DIPG) have a poor prognosis with a median survival that is usually reported to be 9 months, and nearly 90% of children die within 18 months from diagnosis. The mainstay of treatment is radiation to the primary tumor site. Surgical resection does not influence outcome and is often not feasible in this part of the central nervous system.
Many promising drugs for central nervous system (CNS) disorders have failed to attain clinical success due to an intact blood brain barrier (BBB), limiting their access form the systemic circulation into the brain. Systemic administration of high doses may increase delivery to the brain, but this approach risks significant side effects and systemic toxicities. Direct delivery of the drugs to the brain by injection into the parenchyma bypasses the BBB, however, drug distribution form the site of injection tends to be limited. The convection-enhanced delivery (CED) of drugs describes the infusion of drugs under controlled pressure to the brain parenchyma via targeted microcatheter. This technique facilitates and deliver higher drug concentrations in brain tissue or tumor. The BBB can now operate to retain drug and to significantly reduce systemic side effects. In addition, the fact that panobinostat seems to be most efficacious clinically available drug against DIPG cells.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Luca Szalontay, MD
- Phone Number: (212) 305-9770
- Email: ls3399@cumc.columbia.edu
Study Contact Backup
- Name: Jessica Morcone, RNP
- Phone Number: 212-305-9770
- Email: jm4393@cumc.columbia.edu
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Irving Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Aged more than 3 years up to the 18th birthday
- Radiological diagnosis of DIPG with tumor confined to the region of the pons or
- thalami without cystic changes or hematoma obstructing the planned catheter trajectories
- Radiological diagnosis of thalamic gliomas confined to bilateral thalami without cystic changes or hematoma obstructing the planned catheter trajectories
- Radiological features of DIPG: intrinsic, pontine based infiltrative lesion; hypointense in T1 weighted images (T1WIs) and hyperintense in T2 sequences, with mass effect on the adjacent structures and occupying at least 50% of the pons
- No prior therapy is allowed other than involved field radiotherapy (54Gy) and cerebrospinal fluid (CSF) diversion for hydrocephalus, including endoscopic third ventriculostomy (ETV) or a ventriculo-peritoneal shunt. No concomitant medicine or therapies for treatment are permitted while the patient is enrolled in this study.
- Karnofsky performance status or Lansky play score of ≥70 assessed at diagnosis
- Total bilirubin: within normal institutional limits
- Aspartate Aminotransferase (AST)(SGOT)/Alanine Aminotransferase (ALT)(SGPT): ≤ 2.5 × institutional upper limit of normal (ULN)
- Creatinine: within normal institutional limits
- Creatinine clearance: ≥ 60 mL/min/1.73m2 for patients with creatinine levels above institutional normal
- Absolute neutrophil count: ≥ 1,500/μL
- Platelet count: ≥ 100,000/μL - no transfusion within 7 days
- Hemoglobin level: ≥ 10g/dL - no transfusion within 7 days
- Partial Thromboplastin Time (PT) and activated partial thromboplastin time (APTT): within normal institutional limits
- No documented current bleeding disorder
- No medical condition that would preclude general anesthesia
- No severe acute infection or unexplained febrile illness
- Not pregnant or nursing - negative serum pregnancy test if appropriate within 7 days of study entry (adequate contraceptive methods for females and males required)
- No documented allergy to compounds of similar chemical or biologic composition to MTX110 or gadolinium compounds
- Subjects with a history of seizures/epilepsy should be on anticonvulsant medication prior to the first operative procedure on study, with serum levels within a therapeutic range
- Subjects must be able to undergo MR-imaging with gadolinium-based contrast administration (e.g. no ferrous-containing implants, no pacemakers, etc.)
- All subjects or their legal guardians must sign a document of informed consent indicating their understanding of the investigational nature and the potential risks associated with this study. When appropriate, pediatric subjects will be included in all discussions in order to obtain verbal and written assent
Exclusion Criteria:
- Radiological evidence of distant disease outside the pons or thalami
- Radiological evidence of metastatic disease within the central nervous system (CNS) at diagnosis
- Subjects with an uncorrectable bleeding disorder
- Subjects with multifocal or leptomeningeal disease beyond the pons or the thalami
- Subjects with signs of impending herniation or an acute intratumoral hemorrhage
- Subjects that have received or are on concurrent chemotherapy or biologic therapy for the treatment of their tumor
- Subjects who are pregnant or breastfeeding
- Previous experimental or trial-based therapy
- Patients who are known human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C positive. HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with MTX110.
- Patients with systemic diseases which may be associated with unacceptable anesthetic/operative risk
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MTX110 and CED
All patients enrolled in the study will receive infusion of MTX110 and Gadolinium delivered by the CED delivery system directly into the tumor over 9-11 days.
|
Pulses 1 and 2 will be prepared with 30, 60 or 90 uM concentration of MTX110.
The infusate consists of gadolinium and MTX110 (30, 60, or 90 uM) at approximately 1:100 ratio.
CED is the method by which the drug are delivered to the brain under controlled pressure to the brain by targeted micro-catheters.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Adverse Events
Time Frame: Up to six weeks after second infusion
|
Safety of repeated convection-enhanced delivery (CED) of MTX110 will be reported by summarizing the incidence rate of adverse events observed or reported.
Adverse events will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
|
Up to six weeks after second infusion
|
Maximum Tolerated Dose (MTD) of MTX110
Time Frame: 14 days
|
The MTD will be determined based on the number of dose limiting toxicities (DLT) observed in each of the titrated doses.
|
14 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Steady state volume of drug distribution
Time Frame: 14 days
|
Measured by volumetric contrast enhancement intensity on MRI and magnetic resonance (MR) spectroscopy
|
14 days
|
Time to tumor progression/recurrence (PFS)
Time Frame: 2 years
|
PFS is defined as the duration of time from start of MTX110 treatment to time of progression or death from any cause, whichever occurs first.
|
2 years
|
Overall survival (OS) or time to death
Time Frame: 2 years
|
Overall survival is defined as the duration of time from the start of MTX110 treatment to death from any cause.
OS will be measured by follow-up with a study participant every 3-6 months until death for any reason.
|
2 years
|
Score on PedsQL 4.0 Brain Tumor Module
Time Frame: 2 years
|
The 24-item PedsQL 4.0 Brain Tumor Module encompasses six scales: (1) cognitive problems (seven items), (2) pain and hurt (three items), (3) movement and balance (three items), (4) procedural anxiety (three items), (5) nausea (five items), and (6) worry (three items).
Each item is measured with a 5-point Likert scale from 0 (never a problem) to 4 (almost always a problem), which is then transformed on a scale from 0-100.
Higher scores indicate lower problems and therefore a better outcome.
|
2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Luca Szalontay, MD, Columbia University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Brain Neoplasms
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Brain Stem Neoplasms
- Infratentorial Neoplasms
- Glioma
- Diffuse Intrinsic Pontine Glioma
Other Study ID Numbers
- AAAS2936
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diffuse Intrinsic Pontine Glioma
-
National Cancer Institute (NCI)RecruitingRecurrent Malignant Glioma | Recurrent Medulloblastoma | Refractory Malignant Glioma | Refractory Medulloblastoma | Recurrent Diffuse Intrinsic Pontine Glioma | Recurrent Primary Central Nervous System Neoplasm | Refractory Primary Central Nervous System Neoplasm | Refractory Diffuse Intrinsic Pontine...United States, Canada
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Solving Kids' CancerCompletedDiffuse Intrinsic Pontine Glioma (DIPG)United States
-
University of California, San FranciscoTranslational Genomics Research InstituteCompletedDiffuse Intrinsic Pontine Glioma (DIPG)United States
-
University of California, San FranciscoNational Institute of Neurological Disorders and Stroke (NINDS); The Chad-Tough... and other collaboratorsRecruitingDiffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant | Recurrent Diffuse Intrinsic Pontine Glioma | Recurrent Diffuse Midline Glioma, H3 K27M-Mutant | Recurrent WHO Grade III Glioma | WHO Grade III GliomaUnited States, Israel, Australia, Netherlands, Switzerland, New Zealand
-
Burzynski Research InstituteSuspendedDiffuse, Intrinsic Pontine GliomaUnited States
-
University of FloridaAccelerate Brain Cancer Cure; Lyla Nsouli FoundationActive, not recruitingBrain Stem Glioma | Diffuse Intrinsic Pontine Glioma (DIPG)United States
-
Shenzhen Geno-Immune Medical InstituteShenzhen Children's Hospital; Shenzhen Hospital of Southern Medical UniversityUnknownDiffuse Intrinsic Pontine Glioma or GlioblastomaChina
-
Hadassah Medical OrganizationCompletedPediatric Malignant Brain Tumor -Diffuse Intrinsic Pontine GliomaIsrael
-
Pediatric Brain Tumor ConsortiumNational Cancer Institute (NCI)CompletedMalignant Glioma | Recurrent Childhood Ependymoma | Recurrent Medulloblastoma | Recurrent Diffuse Intrinsic Pontine Glioma | Recurrent Atypical Teratoid/Rhabdoid Tumor | Refractory Diffuse Intrinsic Pontine Glioma | CNS Embryonal Tumor, Not Otherwise SpecifiedUnited States
-
Cheng-Chia (Fred) WuFocused Ultrasound FoundationActive, not recruitingDiffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant | Diffuse Pontine and Thalamic GliomasUnited States
Clinical Trials on Infusate with MTX110 and gadolinium
-
The University of Texas Health Science Center,...Midatech Pharma plcRecruitingMedulloblastomaUnited States
-
Imperial College LondonNational Institute for Health Research, United Kingdom; Imperial College Healthcare...WithdrawnMyocardial Fibrosis | Heart Failure | End Stage Renal Failure on Dialysis | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe)United Kingdom
-
Fondation Ophtalmologique Adolphe de RothschildCompleted
-
Moriel VandsburgerTerminatedMyocardial Fibrosis | Healthy | Chronic Kidney DiseaseUnited States
-
Institut National de la Santé Et de la Recherche...CompletedDuchenne or Severe Becker MyopathyFrance
-
Sabine Mueller, MD, PhDPacific Pediatric Neuro-Oncology Consortium; Midatech Pharma US Inc.CompletedDiffuse Intrinsic Pontine GliomaUnited States
-
University of Alabama at BirminghamBracco CorporateActive, not recruitingBreast Malignant Tumor | Breast Benign TumorUnited States
-
NYU Langone HealthActive, not recruiting
-
University Hospital, BordeauxCompletedHypertrophic Cardiomyopathy | Mechanical Hyper-synchronicityFrance
-
Assistance Publique - Hôpitaux de ParisPfizerCompleted